Literature DB >> 14718718

Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis.

S Overeem1, J Dalmau, L Bataller, S Nishino, E Mignot, J Verschuuren, G J Lammers.   

Abstract

Idiopathic narcolepsy is associated with deficient hypocretin transmission. Narcoleptic symptoms have recently been described in paraneoplastic encephalitis with anti-Ma2 antibodies. The authors measured CSF hypocretin-1 levels in six patients with anti-Ma2 encephalitis, and screened for anti-Ma antibodies in patients with idiopathic narcolepsy. Anti-Ma autoantibodies were not detected in patients with idiopathic narcolepsy. Four patients with anti-Ma2 encephalitis had excessive daytime sleepiness; hypocretin-1 was not detectable in their cerebrospinal fluid, suggesting an immune-mediated hypocretin dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718718      PMCID: PMC2574537          DOI: 10.1212/01.wnl.0000101718.92619.67

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.

Authors:  S Overeem; E Mignot; J G van Dijk; G J Lammers
Journal:  J Clin Neurophysiol       Date:  2001-03       Impact factor: 2.177

2.  CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.

Authors:  B Ripley; S Overeem; N Fujiki; S Nevsimalova; M Uchino; J Yesavage; D Di Monte; K Dohi; A Melberg; G J Lammers; Y Nishida; F W Roelandse; M Hungs; E Mignot; S Nishino
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

3.  Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602.

Authors:  John Logan Black; Lois E Krahn; V Shane Pankratz; Michael Silber
Journal:  Sleep       Date:  2002-11-01       Impact factor: 5.849

4.  Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.

Authors:  M R Rosenfeld; J G Eichen; D F Wade; J B Posner; J Dalmau
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

5.  Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; S Nevsimalova; G J Lammers; J Vankova; M Okun; W Rogers; S Brooks; E Mignot
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.

Authors:  R Voltz; S H Gultekin; M R Rosenfeld; E Gerstner; J Eichen; J B Posner; J Dalmau
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

7.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

Review 9.  The neurobiology, diagnosis, and treatment of narcolepsy.

Authors:  Thomas E Scammell
Journal:  Ann Neurol       Date:  2003-02       Impact factor: 10.422

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

  10 in total
  21 in total

Review 1.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

2.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

Review 3.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

Review 4.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

5.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

6.  Sleep disturbances are common in patients with autoimmune encephalitis.

Authors:  Margaret S Blattner; Gabriela S de Bruin; Robert C Bucelli; Gregory S Day
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

7.  Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study.

Authors:  Iñigo Rojas-Marcos; Francesc Graus; Gema Sanz; Arturo Robledo; Carlos Diaz-Espejo
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

Review 8.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 9.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

10.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.